Client Alerts & Insights
Tax Guidance on Paycheck Protection Program (PPP)
November 19, 2020
Authored By:
The IRS has previously released guidance saying that expenses paid with Paycheck Protection Program (PPP) proceeds which would otherwise be deductible will not be permitted to be deducted. There was much hope in the business community that this ruling would be overturned since it effectively reduces the benefit of PPP by a company’s marginal tax rate.
Unfortunately, the IRS released another revenue ruling on November 18, 2020 affirming its previous stance. The ruling can be found here and essentially states that if there is a reasonable expectation that a PPP loan will be forgiven then the PPP borrower cannot deduct expenses paid for with PPP proceeds for tax purposes.
Given that this is the second time the IRS has taken this stance, it is likely that legislation would be needed from Congress to change directions.
The impact on taxes can have a significant impact on cash flows and also on financial covenant calculations under credit facilities.
For more information, please contact your Benesch representative.
Matthew P. Delguyd at mdelguyd@beneschlaw.com or 216.363.4627.
Latest News
Supreme Court Clarifies Judicial Estoppel Standard in Bankruptcy Nondisclosure Cases
The U.S. Supreme Court rejected a rigid rule that often blocked debtors from pursuing claims they failed to disclose in bankruptcy. Courts must now look at the full circumstances before deciding whether an omission was intentional or an honest mistake.
Federal Court Hands Major Win to Tissue Product Manufacturers – FDA’s HCT/P Classification Decision for Umbilical Cord–Derived Product CORDGRAFT Rejected
On March 18, 2026, Chief Judge Brian C. Wimes of the U.S. District Court for the Western District of Missouri issued a significant decision overturning the U.S. Food and Drug Administration’s (“FDA”) classification of Vitti Labs’ umbilical cord–derived product, CORDGRAFT.
Science-Backed But Not FDA-Approved: New Lawsuit Challenges FDA’s Rejection of 114 Health-Related Advertising Claims
A new lawsuit challenges the FDA’s rejection of 114 health-related advertising claims for supplements, arguing that the agency’s narrow interpretation of what counts as an “authoritative statement” unfairly blocks science-backed—but not FDA-approved—claims from appearing on product labels.
When ChatGPT Lies: What the First Wave of AI Defamation Cases Means for Plaintiffs
The common argument made by plaintiffs that differences in alleged misrepresentations are transcended by the center of the gravity of the alleged fraud should not be addressed through the typical approach of just comparing the level of variance of the representations in the case at issue with that in the relevant precedent.